ABSTRACT
Objective: To investigate the association between serum omentin-1 levels and adverse cardiac events in patients with hypertrophic cardiomyopathy [HCM]
Subjects and Methods: This prospective, observational study included 87 patients with HCM and 50 age- and sex-matched control subjects. Serum omentin-1 and brain natriuretic peptide [BNP] levels were measured in all subjects, using enzyme-linked immunosorbent assay and electrochemiluminescence, respectively. Patients with HCM were divided into 2 groups acaccording to their omentin levels, i.e., low: .291 ng/mL [n = 48] and high: > 291 ng/mL [n = 39]. Cardiac mortality, hospitalization due to heart failure, and implantable cardioverter-defibrillator [ICD] implantation were considered adverse cardiac events. Statistical analysis included uni- and multivariant logistic regression, receiver-operating characteristic [ROC] analysis, and the Kaplan-Meier method
Results: Serum omentin-1 levels were significantly lower in the obstructive [253.9 +/- 41.3 ng/mL] and nonobstructive [301.9 +/- 39.8 ng/mL] HCM groups than in the control group [767.1 +/- 56.4 ng/mL], p < 0.001, respectively. The BNP levels were higher in the obstructive and nonobstructive HCM groups than in the control group [269.5 +/- 220, 241.0 ] 227, and 24.0 +/- 18.9 pg/mL, respectively, p < 0.001]. The Kaplan-Meier analysis indicated that patients with low omentin-1 levels showed a significantly higher [48.2%] 2-year cumulative incidence of overall adverse cardiac events than those with high omentin- 1 levels [16.2%] [log-rank test, p = 0.001]. In the multivariate logistic regression analysis, omentin-1, interventricular septum [IVS] thickness, and male gender were independent predictors of adverse cardiac events in the follow-up
Conclusion: Omentin-1 levels were lower in patients with HCM than in the control group, and this was associated with worse cardiac outcomes